Douglas Johnson

49PUBLICATIONS
249CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Jun 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

|May 05, 2026
A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapy.

|Apr 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

|Feb 18, 2026
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Douglas B Johnson, Amin H Nassar, Ayesha Aijaz

|Jan 12, 2026
RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance.

Chi Yan, Weifeng Luo, Jinming Yang

|Oct 01, 2025
Long-Term Toxicities of Immune Checkpoint Inhibitors.

Preethy E Abraham, Douglas B Johnson

Pageof 9

Frequent Collaborators

7 joint publications

Justin M Balko

5 joint publications

Elad Sharon

4 joint publications

Juan Qin

3 joint publications

Alexander N Shoushtari